TD Tele-Doc Weight Loss review

TD may suit Virginia residents who want regular support alongside prescription care. Confirm the complete patient cost and insurance status directly: neither the $199 headline nor the Medicare messaging provides a dependable coverage or monthly-price promise.

TD Tele-Doc Weight Loss presents itself as a telehealth medical practice with a Richmond, Virginia address. Its physician page names Peter Wilbanks, MD and Michael Perini, MD. Their titles and career descriptions are provider disclosures; they do not establish independently checked credentials or who would treat an individual patient.

The privacy page carries a Privia Health organized healthcare arrangement notice and describes affiliated care centers as legally separate, with individual professionals independent. The incorporated practice name beyond the TD brand is not clearly established. Before beginning care, ask which legal practice will hold your medical record and bill for visits.

The terms page names RX3 Compounding Pharmacy at a Chester, Virginia address. That is a useful named-pharmacy disclosure, but does not explicitly assign RX3 to every prescription or plan. Confirm your actual dispenser and whom to contact about preparation, delivery and refills.

The Pathway program begins with a tele-visit assessment from a computer or smartphone. It describes individualized nutrition choices, while the about page emphasizes weekly virtual visits and remote patient monitoring using connected biometric information. Ask which clinician conducts those visits and how progress or medication problems are handled between appointments.

A history-dependent starter box may contain a biometric scale, measuring tape, bag and a first month of recommended supplements. The description does not guarantee every item for every patient or establish that prescription medication is included. Device monitoring and supplements should be considered separately from the medication quote.

The medication page limits telemedicine to Virginia residents, and the Pathway page describes service throughout Virginia. A Maryland coming-soon image does not establish current Maryland access. Uniform numeric age and BMI thresholds are not clearly published in the program material; eligibility requires clinical assessment.

TD says approved medication and supplies can ship to the home or office. A standard shipping fee, delivery window and prescription supply duration are not established. The Privia privacy notice addresses treatment, payment, operations and patient record rights, but its presence does not independently verify every technical security or data-sharing practice.

The homepage advertises semaglutide starting at $199 without specifying a billing period, supply duration, dose, precise product, inclusions or first-versus-refill price. Treat this as an incomplete starting amount. It cannot support a $199 monthly medication budget or an all-inclusive monthly comparison.

A free initial consultation is advertised, but that does not make subsequent medical treatment or prescribing visits free. No complete public schedule establishes medication prices by dose, a recurring membership fee, an upfront package total or shipping charges. Request separate initial and ongoing totals covering visits, medication, equipment, laboratory work and delivery.

Insurance statements conflict. A prominent homepage heading describes Medicare network participation, while multiple notices say Medicare and Medicaid cannot be accepted. The medication and about pages instead discuss most commercial or most insurance plans. Obtain a benefit determination for your exact plan and service before relying on either Medicare statement.

The about page says insurance may cover weekly visits and monitoring equipment. That is distinct from medication coverage, deductibles, copays and prior authorization. Ask whether the practice bills the insurer, what you owe if a claim is denied and whether your chosen medication has a separate pharmacy benefit.

The linked terms provide SMS conditions and a pharmacy address rather than a complete treatment purchase policy. Public cancellation deadlines, prescription refund rules, no-show charges, refill intervals and long-term commitment are not established. Obtain those terms in writing before committing to ongoing care.

The medication page names Wegovy, Ozempic, Zepbound and Mounjaro as possible options based on history and insurance coverage. It expressly offers compounded semaglutide injections. Its tirzepatide FAQ describes a weekly subcutaneous injection, but does not establish an explicit compounded tirzepatide offer.

Testimonials about drops do not establish a current oral prescription option. Confirm the actual branded or compounded product, indication, dose, formulation and dispensing pharmacy for the proposed plan. Compounded medication is not FDA approved, and a branded medication’s name does not establish that it is appropriate or covered for every patient.